B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhance Cardiac Structure, Function, And Amyloid Burden In Individuals With Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today

BridgeBio Pharma To Present Two Oral Presentations, Three Posters On New Acoramidis Data In Individuals With Transthyretin Amyloid Cardiomyopathy At European Society Of Cardiology Congress 2026

8-K filing — BridgeBio Pharma, Inc. (BBIO)

Filed: 2026-08-17 AccNo: 0001140361-26-033282 Size: 477 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

BridgeBio Pharma's stock has surged 29% in three months, driven by strong performance of its FDA-approved heart medication Attruby, which saw sales more than triple year-over-year to $222 million in Q2. With 16 out of 17 analysts recommending a buy and three promising drugs in late-stage development under FDA review, Wall Street believes the stock has further upside potential despite the company remaining unprofitable.